Open ICICI
3-in-1 Account
Manage your Savings, Demat and Trading Account conveniently at one place
Manage your Savings, Demat and Trading Account conveniently at one place
News: As per media sources the US District Court dismissed (Lupin and Zydus) generic companies arguments on interpreting the '189 patent for Astellas overactive bladder medication, Myrbetriq. The companies had requested the court to apply a consistent interpretation of the term "reduced food effect" across both the 189 and 451 patents. However, the court sided with Astellas interpretation.
View: The ongoing litigation and the US court interpretation covers patents 189 and 451 of gMyrbetriq (mirabegron) besides the earlier unfavourable interpretation patent 780. Both the management have already decided to challenge all the patents in a jury trial next year and they continue to launch the product at risk. This stance anyway was cleared at the time of Q4 concalls.
Impact: Neutral